AbstractHepcidin is a key hormonal regulator of systemic iron homeostasis and its expression is induced by iron or inflammatory stimuli. Genetic defects in iron signaling to hepcidin lead to “hepcidinopathies” ranging from hereditary hemochromatosis to iron-refractory iron deficiency anemia, which are disorders caused by hepcidin deficiency or excess, respectively. Moreover, dysregulation of hepcidin is a pathogenic cofactor in iron-loading anemias with ineffective erythropoiesis and in anemia of inflammation. Experiments with preclinical animal models provided evidence that restoration of appropriate hepcidin levels can be used for the treatment of these conditions. This fueled the rapidly growing field of hepcidin therapeutics. Several hepcidin agonists and antagonists, as well as inducers and inhibitors of hepcidin expression have been identified to date. Some of them were further developed and are currently being evaluated in clinical trials. This review summarizes the state of the art. View Full-Text
Share & Cite This Article
Katsarou, A.; Pantopoulos, K. Hepcidin Therapeutics. Pharmaceuticals 2018, 11, 127.
Katsarou A, Pantopoulos K. Hepcidin Therapeutics. Pharmaceuticals. 2018; 11(4):127.Chicago/Turabian Style
Katsarou, Angeliki; Pantopoulos, Kostas. 2018. "Hepcidin Therapeutics." Pharmaceuticals 11, no. 4: 127.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.